

## Fezolinetant

## Chemical Properties


CAS No. : 1629229-37-3

Formula: C<sub>16</sub>H<sub>15</sub>FN<sub>6</sub>O<sub>5</sub>

Molecular Weight: 358.39

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Fezolinetant (ESN-364) is a neurokinin-3 receptor antagonist that is being investigated for menopausal hot flashes.
Targets(IC50)	Neurokinin receptor
In vivo	<b>METHODS:</b> Fezolinetant (ESN-364) (1 mg/kg, intravenously) was administered to ovariectomized ewes, and LH/FSH measurements or pharmacokinetic analysis were performed. <b>RESULTS</b> Fezolinetant reversibly inhibited the regular pulsatile secretion of LH in ovariectomized ewes; plasma FSH levels did not change during the experimental period. [1] <b>METHODS:</b> Fezolinetant (5 mg/kg, oral) was administered to castrated cynomolgus monkeys, and LH/FSH measurements or pharmacokinetic analysis were performed. <b>RESULTS</b> Fezolinetant decreased plasma LH, but not FSH, in castrated monkeys. [1]

## Solubility Information

Solubility	DMSO: 10 mg/mL (27.9 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.7903 mL	13.9513 mL	27.9026 mL
5 mM	0.5581 mL	2.7903 mL	5.5805 mL
10 mM	0.279 mL	1.3951 mL	2.7903 mL
50 mM	0.0558 mL	0.279 mL	0.5581 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Fraser GL, et al. The NK3 Receptor Antagonist ESN364 Interrupts Pulsatile LH Secretion and Moderates Levels of Ovarian Hormones Throughout the Menstrual Cycle. *Endocrinology*. 2015 Nov;156(11):4214-25.

Xu W, Li G, Chen Y, et al. A novel antidiuretic hormone governs tumour-induced renal dysfunction. *Nature*. 2023: 1-8.

Lee A. Fezolinetant: First Approval. *Drugs*. 2023 Aug;83(12):1137-1141.

A novel antidiuretic hormone governs tumour-induced renal dysfunction

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481